Cephalon highlights positive data from large-scale Nuvigil trial

Pharmaceutical Company Product News

Cephalon has published new clinical trial data that demonstrates the benefits its drug Nuvigil can offer to sufferers of excessive sleepiness associated with shift work disorder.

The treatment has been analysed among 383 patients in a six-week placebo-controlled phase IV study, which was the largest shift work disorder trial of its kind ever conducted.

It was found that Nuvigil was able to improve subjects' overall clinical condition late in their shifts, including during the commute home, while patients using the Cephalon drug also scored higher on the Global Assessment of Functioning scale.

Dr Milton Erman, the study's lead investigator and a clinical professor of psychiatry at the University of California San Diego, said this shows the drug's importance for those with unconventional working hours.

"This study reinforces the need for healthcare professionals to learn more about this disorder and about how treatment options like Nuvigil may be of help," he added.

Earlier this month, Cephalon posted strong financial results for the first quarter of 2011, while also announcing the agreement of a deal that will see the company acquired by Teva.

See all the latest jobs in Pharmaceutical
Return to news